Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. SPY
3. ALAR
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. CCHGY
9. PRY:IM
10. PRYMY

Go back to Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

Stifel Downgrades Rapt Therapeutics (RAPT) to Hold

November 12, 2024 4:04 PM EST

Stifel analyst Alex Thompson downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Hold with a price target of $2.00 (from $7.00).

The analyst comments "We are downgrading RAPT to Hold following the recent Zelnecirnon program termination (LINK). RAPT discontinued the program following FDA feedback suggesting... More